Page last updated: 2024-11-04

1-methylimidazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-methyl-1H-imidazole : A 1H-imidazole having a methyl substituent at the N-1 position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1390
CHEMBL ID543
CHEBI ID113454
MeSH IDM0069332

Synonyms (82)

Synonym
n-methylimidazole
nsc88064
wln: t5n cnj a1
nsc-88064
ec 210-484-7
unii-p4617qs63y
p4617qs63y ,
imidazole, 1-methyl-
einecs 210-484-7
nsc 88064
EU-0100831
lopac-m-8878
NCGC00015702-01
bdbm7884
LOPAC0_000831
616-47-7
inchi=1/c4h6n2/c1-6-3-2-5-4-6/h2-4h,1h
1-methyl-1h-imidazole
1h-imidazole, 1-methyl-
1-methylimidazole ,
1-methylimidazole, reagentplus(r), 99%
NCGC00094162-01
NCGC00094162-02
1-methylimidazole, >=99%, purified by redistillation
NCGC00015702-02
CHEBI:113454 ,
M 8878
NCGC00015702-04
CHEMBL543
3-methyl-1h-imidazol-3-ium
M0508
AKOS000119840
HMS3262H03
1-methyl-imidazole
BBL011447
CCG-204915
NCGC00015702-03
FT-0671848
STL146559
FT-0632577
LP00831
n1-methylimidazole
thiamazole impurity b [ep impurity]
araldite dy 070
tox21_500831
NCGC00261516-01
1-methyl-(1h)-imidazole
1-n-methylimidazole
n-methyl-imidazole
1-methylimidazol
3-methylimidazole
n-methyl imidazole
1-methylimdazole
n-methyl-imidazol
1-methyl imidazole
n-methylimidazol
dtxcid6030863
dtxsid6052291 ,
NCGC00357222-01
cas-616-47-7
tox21_304006
Q-200126
STR00990
1-methyl-1h-imidazole #
PS-9372
mfcd00005292
F0001-1635
1-methylimidazole, puriss., >=99.0% (gc)
CS-W008580
cap b (1-methylimidazole 16% in thf), for oligonucleotide synthesis, filtered through a 1mum filter
D70869
1-methylimidazole, vetec(tm) reagent grade, 98%
1-methyl-1h-imidazole; thiamazole imp. b (ep); thiamazole impurity b
sr-01000076013
SR-01000076013-1
Q4545792
SDCCGSBI-0050808.P002
1-methyl-1h-imidazole;n-methylimidazole;1h-imidazole, 1-methyl-
BCP29437
EN300-21628
PD015169
Z104506032
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
imidazolesA five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
histamine biosynthesis421

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.50120.003245.467312,589.2998AID2517
Chain A, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID886
endonuclease IVEscherichia coliPotency1.25890.707912.432431.6228AID1708
dopamine D1 receptorHomo sapiens (human)Potency0.11580.00521.30228.1995AID624455
NFKB1 protein, partialHomo sapiens (human)Potency0.00630.02827.055915.8489AID895; AID928
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency61.13060.003041.611522,387.1992AID1159552
arylsulfatase AHomo sapiens (human)Potency8.49211.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.79430.035520.977089.1251AID504332
flap endonuclease 1Homo sapiens (human)Potency37.68580.133725.412989.1251AID588795
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)2,697.74000.00011.753610.0000AID428564
Glutaminyl-peptide cyclotransferaseHomo sapiens (human)Ki30.00000.26202.93587.0000AID1796106
Glutaminyl-peptide cyclotransferaseMus musculus (house mouse)Ki23.00006.40006.40006.4000AID1796111
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Epoxide hydrolase 1Rattus norvegicus (Norway rat)E10012,000.00006.20006.20006.2000AID208343
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (21)

Processvia Protein(s)Taxonomy
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
peptidyl-pyroglutamic acid biosynthetic process, using glutaminyl-peptide cyclotransferaseGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
protein modification processGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (25)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
protein bindingGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
zinc ion bindingGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
glutaminyl-peptide cyclotransferase activityGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
extracellular regionGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
specific granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
extracellular exosomeGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
tertiary granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
ficolin-1-rich granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (34)

Assay IDTitleYearJournalArticle
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1796106QC Inhibition Testing from Article 10.1021/jm050756e: \\The first potent inhibitors for human glutaminyl cyclase: synthesis and structure-activity relationship.\\2006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
The first potent inhibitors for human glutaminyl cyclase: synthesis and structure-activity relationship.
AID1796111QC Inhibition Testing from Article 10.1021/bi051142e: \\Isolation, catalytic properties, and competitive inhibitors of the zinc-dependent murine glutaminyl cyclase.\\2005Biochemistry, Oct-11, Volume: 44, Issue:40
Isolation, catalytic properties, and competitive inhibitors of the zinc-dependent murine glutaminyl cyclase.
AID25595Dissociation constant was evaluated1996Journal of medicinal chemistry, May-24, Volume: 39, Issue:11
Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition.
AID25092Ionization constant (pKa)1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Direct prediction of dissociation constants (pKa's) of clonidine-like imidazolines, 2-substituted imidazoles, and 1-methyl-2-substituted-imidazoles from 3D structures using a comparative molecular field analysis (CoMFA) approach.
AID208355Maximum enhancement of styrene oxide hydrolase activity was reported at compound concentration of 5e-2M1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Structural features of imidazole derivatives that enhance styrene oxide hydrolase activity in rat hepatic microsomes.
AID206966Sterilization time for contact germicidal efficiency (CGE) of salt was tested against Staphylococcus aureus at pH 7.0, concentration 254 ppm1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Soft drugs. 1. Labile quaternary ammonium salts as soft antimicrobials.
AID26810Partition coefficient (logP)1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Structural features of imidazole derivatives that enhance styrene oxide hydrolase activity in rat hepatic microsomes.
AID1134914Dissociation constant, pKa of the compound1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Lysosomotropic agents. 1. Synthesis and cytotoxic action of lysosomotropic detergents.
AID70215Enhancement of epoxide hydrolase activity1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Structural features of imidazole derivatives that enhance styrene oxide hydrolase activity in rat hepatic microsomes.
AID164414Sterilization time for contact germicidal efficiency (CGE) of salt was tested against Pseudomonas aeruginosa at pH 7.0, concentration 254 ppm1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Soft drugs. 1. Labile quaternary ammonium salts as soft antimicrobials.
AID208343Enhanced styrene oxide hydrolase activity pH 8.71985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Structural features of imidazole derivatives that enhance styrene oxide hydrolase activity in rat hepatic microsomes.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID428564Inhibition of CYP3A42009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.
AID210078Sterilization time for contact germicidal efficiency (CGE) of salt was tested against Streptococcus pyogenes at pH 7.0, concentration 254 ppm1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Soft drugs. 1. Labile quaternary ammonium salts as soft antimicrobials.
AID26397Dissociation constant (pKa, calculated using GNN method)1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 2. Applications.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (209)

TimeframeStudies, This Drug (%)All Drugs %
pre-199027 (12.92)18.7374
1990's20 (9.57)18.2507
2000's72 (34.45)29.6817
2010's80 (38.28)24.3611
2020's10 (4.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.89 (24.57)
Research Supply Index5.37 (2.92)
Research Growth Index4.84 (4.65)
Search Engine Demand Index89.08 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (54.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (0.93%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other212 (99.07%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]